Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on June 10, 2025
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
GlobeNewswire
·
June 10, 2025
SYMBRAVO represents a novel multi-mechanistic approach to treating migraine that addresses multiple pathways underlying a migraine attack SYMBRAVO On My Side offers comprehensive patient support services including access and prescription drug support NEW …
Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease
GlobeNewswire
·
June 10, 2025
Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease AstraZeneca exercises option to license the first candidate from the IBD joint research program for further development and commercialization …
Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention
GlobeNewswire
·
June 10, 2025
CHATHAM, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth …
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
GlobeNewswire
·
June 10, 2025
MRT-8102, a highly selective NEK7-directed molecular glue degrader (MGD) developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation, expands Monte Rosa’s clinical I…
Pharvaris Announces Annual Meeting of Shareholders
GlobeNewswire
·
June 10, 2025
ZUG, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases …
Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation’s First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs
GlobeNewswire
·
June 10, 2025
LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational …
Apothecare and FIKA Cannabis Partner to Deliver Pharmacist-Led Cannabis Consultations
GlobeNewswire
·
June 10, 2025
TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Apothecare, Canada’s leading pharmacist-led cannabis consultation service, has partnered with FIKA Cannabis, one of the country’s fastest-growing lifestyle cannabis retailers, to launch professional cannabis …
Boehringer Ingelheim and Eko Health Inc. enter digital health collaboration to improve heart murmur detection in dogs
GlobeNewswire
·
June 10, 2025
A novel canine-specific detection algorithm is designed to improve early identification of heart disease and expand access to life-extending cardiac care for dogs Ingelheim, Germany, and San Francisco, Calif., June 10, 2025 | Boehringer Ingelheim, a global …
Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site
GlobeNewswire
·
June 10, 2025
UHealth — University of Miami Health System and the University of Miami Miller School of Medicine provide world-class research and renowned clinical expertise in spine surgery CLARITY is a prospective, randomized clinical trial designed to demonstrate …
Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
GlobeNewswire
·
June 10, 2025
- The U.S. Food and Drug Administration (FDA) identified deficiencies at a third-party manufacturing vendor - FDA to provide final decision by PDUFA action date of June 28, 2025 LOS ALTOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, …
XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology
GlobeNewswire
·
June 10, 2025
Freising, Germany, June 10, 2025 — XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced today that it has entered into a worldwide License, Development and Commercialization Agreement with Grifols, a global …
HepaRegeniX Doses First Patient in Phase Ib Trial with Small Molecule Inhibitor HRX-215 to Promote Liver Regeneration
GlobeNewswire
·
June 10, 2025
Tuebingen, Germany, June 10, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, today announced that the first patient has been dosed in their Phase Ib clinical trial of its …
मोटापा-रोधी ओरल दवा कार्यक्रम में RenaissThera ने हासिल की शोध की अहम उपलब्धि
GlobeNewswire
·
June 10, 2025
बेंगलुरु, भारत, June 10, 2025 (GLOBE NEWSWIRE) -- बेंगलुरु स्थित बायोटेक्नोलॉजी कंपनी RenaissThera प्राइवेट लिमिटेड ने अपने मोटापा रोधी दवा कार्यक्रम के तहत ग्लूकोज़-डिपेंडेंट इंस्युलिनोट्रॉपिक पोलिपेप्टाइड रिसेप्टर (GIPR) को लक्ष्य करते हुए एक महत्वपूर्ण …
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
GlobeNewswire
·
June 10, 2025
BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited (“RenaissThera”), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic …
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
GlobeNewswire
·
June 10, 2025
MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge …